Published in Head Neck Oncol on January 12, 2009
Lentiviral vector-based therapy in head and neck cancer (Review). Oncol Lett (2013) 0.83
Surfing the p53 network. Nature (2000) 35.36
Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell (1995) 7.34
An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science (1996) 5.97
Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis. Genes Dev (1993) 5.33
a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med (2000) 4.15
Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med (2001) 4.02
China approves world's first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst (2006) 2.20
Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol (2001) 2.03
An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. J Clin Oncol (2003) 1.78
Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol (1998) 1.76
Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J Virol (1998) 1.72
Clinical trials with oncolytic adenovirus in China. Curr Cancer Drug Targets (2007) 1.62
A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res (2000) 1.59
Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res (2000) 1.55
p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection. J Virol (1998) 1.44
Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). Nat Med (2000) 1.31
Retracted Permanent cardiovascular protection from hypertension by the AT(1) receptor antisense gene therapy in hypertensive rat offspring. Circ Res (1999) 1.16
A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience). Ann Surg Oncol (2000) 1.10
Carcinoma cell lines become sensitive to DNA-damaging agents by the expression of the adenovirus E1A gene. Oncogene (1996) 1.03
Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers. Clin Cancer Res (1999) 0.99
Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer. Clin Cancer Res (2001) 0.99
Clinical highlights from the National Cancer Data Base, 1999. CA Cancer J Clin (1999) 0.95
Gendicine: the first commercial gene therapy product. Hum Gene Ther (2005) 0.91
A multicenter phase II study of tgDCC-E1A for the intratumoral treatment of patients with recurrent head and neck squamous cell carcinoma. Head Neck (2002) 0.90
INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201. Drugs R D (2007) 0.88
Clinical experience with HLA-B7 plasmid DNA/lipid complex in advanced squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg (2001) 0.82
Expression of the type I DNA topoisomerase gene in adenovirus-5 infected human cells. Nucleic Acids Res (1990) 0.82
The adenoviral transcription factor, E1A 13S, trans-activates the human tumor necrosis factor-alpha promoter. Virus Res (1996) 0.80
Epigenetic information and estrogen receptor alpha expression in breast cancer. Oncologist (2006) 1.70
Use of autologous platelet-rich plasma (PRP) in periodontal defect treatment after extraction of impacted mandibular third molars. J Oral Maxillofac Surg (2005) 1.68
Transcriptional regulation of HIV-1 gene expression by p53. Cell Cycle (2010) 1.47
Molecular basis of angiogenesis and cancer. Oncogene (2003) 1.38
Ezh2 reduces the ability of HDAC1-dependent pRb2/p130 transcriptional repression of cyclin A. Oncogene (2004) 1.16
Ultrasound guided site specific gene delivery system using adenoviral vectors and commercial ultrasound contrast agents. J Cell Physiol (2006) 1.07
Immunohistochemical analysis of pRb2/p130, VEGF, EZH2, p53, p16(INK4A), p27(KIP1), p21(WAF1), Ki-67 expression patterns in gastric cancer. J Cell Physiol (2007) 1.02
Developing an effective gene therapy for prostate cancer: New technologies with potential to translate from the laboratory into the clinic. Discov Med (2011) 1.01
Rapid selection and proliferation of CD133+ cells from cancer cell lines: chemotherapeutic implications. PLoS One (2010) 0.98
Chondrosarcoma of the jaw: a closer look at its management. J Oral Maxillofac Surg (2008) 0.98
Platelet-rich plasma and resorbable membrane for prevention of periodontal defects after deeply impacted lower third molar extraction. J Oral Maxillofac Surg (2009) 0.97
Gene-expression analysis identifies novel RBL2/p130 target genes in endemic Burkitt lymphoma cell lines and primary tumors. Blood (2007) 0.96
Expression of RB2/p130 tumor-suppressor gene in AIDS-related non-Hodgkin's lymphomas: implications for disease pathogenesis. Hum Pathol (2002) 0.91
Omega-3 eicosapentaenoic acid decreases CD133 colon cancer stem-like cell marker expression while increasing sensitivity to chemotherapy. PLoS One (2013) 0.90
Expression of cell cycle-regulated proteins pRB2/p130, p107, E2F4, p27, and pCNA in salivary gland tumors: prognostic and diagnostic implications. Clin Cancer Res (2005) 0.90
Cadmium induces p53-dependent apoptosis in human prostate epithelial cells. PLoS One (2012) 0.90
How does the human RUNX3 gene induce apoptosis in gastric cancer? Latest data, reflections and reactions. Cancer Biol Ther (2006) 0.89
TNF-alpha signal transduction in rat neonatal cardiac myocytes: definition of pathways generating from the TNF-alpha receptor. FASEB J (2002) 0.88
Immunohistochemical evaluation of pRb2/p130, VEGF, EZH2, p53, p16, p21waf-1, p27, and PCNA in Barrett's esophagus. J Cell Physiol (2006) 0.86
New palatal distraction device by both bone-borne and tooth-borne force application in a paramedian bone anchorage site: surgical and occlusal considerations on clinical cases. J Craniofac Surg (2014) 0.86
pRb2/p130 and VEGF expression in endometrial carcinoma in relation to angiogenesis and histopathologic tumor grade. Cancer Biol Ther (2006) 0.85
Intraoral epimucosal fixation for reducible maxillary fractures of the jaws; surgical considerations in comparison to current techniques. J Craniofac Surg (2014) 0.83
pRb2/p130 promotes radiation-induced cell death in the glioblastoma cell line HJC12 by p73 upregulation and Bcl-2 downregulation. Oncogene (2002) 0.83
Adenoviral gene therapy in head and neck cancer. Drug News Perspect (2006) 0.83
Outcome of 50 consecutive sinus lift operations. Br J Oral Maxillofac Surg (2005) 0.82
Human immunodeficiency virus type 1 (HIV-1) derived vectors: safety considerations and controversy over therapeutic applications. Eur J Dermatol (2003) 0.82
Ridge Expansion by Flapless Split Crest and Immediate Implant Placement: Evolution of the Technique. J Craniofac Surg (2016) 0.81
Chin Wing Osteotomy for Bilateral Goldenhar Syndrome Treated by "Chin Wing Mentoplasty": Aesthetic, Functional, and Histological Considerations. J Craniofac Surg (2015) 0.81
Cdk9 phosphorylates Pirh2 protein and prevents degradation of p53 protein. Cell Cycle (2013) 0.81
A Patient With a Rare Single Mandibular Localization of Non-Hodgkin B-Cell Lymphoma: Early Differential Diagnosis With Dental Lesions. J Craniofac Surg (2015) 0.80
A new palatal distractor device for bodily movement of maxillary bones by rigid self-locking miniplates and screws system. J Craniofac Surg (2013) 0.80
Transient production of retroviral- and lentiviral-based vectors for the transduction of Mammalian cells. Methods Mol Biol (2004) 0.80
One-step transversal palatal distraction and maxillary repositioning: technical considerations, advantages, and long-term stability. J Craniofac Surg (2011) 0.79
Microbubble-assisted p53, RB, and p130 gene transfer in combination with radiation therapy in prostate cancer. Curr Gene Ther (2013) 0.79
Stem cells in cancer therapy: From their role in pathogenesis to their use as therapeutic agents. Drug News Perspect (2010) 0.79
Maxillary constriction treated by a new palatal distractor device: surgical and occlusal evaluations of 10 patients. J Craniofac Surg (2010) 0.78
Benzyl isothiocyanate inhibits HNSCC cell migration and invasion, and sensitizes HNSCC cells to cisplatin. Nutr Cancer (2014) 0.78
pRB2/p130 target genes in non-small lung cancer cells identified by microarray analysis. Oncogene (2003) 0.77
Osteodistraction With Dental Implant-Borne Devices for Bone Regeneration in Atrophied Premaxilla. J Craniofac Surg (2016) 0.77
Targeting a newly established spontaneous feline fibrosarcoma cell line by gene transfer. PLoS One (2012) 0.77
New Technique for Mandibular Symphyseal Distraction by a Double-Level Anchorage and Fixation System: Advantages and Results. J Craniofac Surg (2016) 0.77
Interview with the retinoblastoma family members: do they help each other? J Cell Physiol (2002) 0.77
Tumor suppressor genes as cancer therapeutics. Drug News Perspect (2007) 0.77
Determination of functional viral titer by drug-resistance colony assay, expression of green fluorescent protein, and beta-galactoside staining. Methods Mol Biol (2004) 0.76
Interplay between the retinoblastoma related pRb2/p130 and E2F-4 and -5 in relation to JCV-TAg. J Cell Physiol (2007) 0.76
Outcome of 47 consecutive sinus lift operations using aragonitic calcium carbonate associated with autologous platelet-rich plasma: clinical, histologic, and histomorphometrical evaluations. J Craniofac Surg (2009) 0.75
Antiangiogenic drugs currently used for colorectal cancer: what other pathways can we target to prolong responses? Drug News Perspect (2007) 0.75
Efficacy of abiraterone acetate in post-docetaxel castration-resistant prostate cancer. Expert Rev Anticancer Ther (2010) 0.75
Osteodistraction With Dental Implant-Borne Devices for Bone Regeneration in Atrophied Premaxilla. J Craniofac Surg (2016) 0.75
Retroviral and lentiviral vector titration by the analysis of the activity of viral reverse transcriptase. Methods Mol Biol (2004) 0.75
The limitless role of p53 in cell cycle machinery: good news or bad news? Cancer Biol Ther (2006) 0.75
New Techniques in Relation to New Concepts of the Aesthetic of the Face: Technical Considerations and Aesthetic Evaluation. J Craniofac Surg (2016) 0.75
p53 and the malignant progression of Barrett's esophagus. J Cell Physiol (2006) 0.75
Adenoviral gene therapy in high-grade malignant glioma. Drug News Perspect (2010) 0.75
Epigenome-derived drugs: recent advances and future perspectives. Drug News Perspect (2007) 0.75
Management of Zygomatic Fractures in Young Patients: Technical Modifications for Aesthetic and Functional Results. J Craniofac Surg (2016) 0.75